GlassScriptPhysician profile
Kishin Ramani
NPI 1932163045
$15,219.00
in general payments reported to CMS, 2019-2025
43 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2020: $1,434 · 2021: $2,599 · 2022: $2,826 · 2023: $1,925 · 2024: $2,350 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,079.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,313.49 | 2019-2025 | |
| Amgen INC. | $1,375.02 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,286.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $994.05 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Kestra Medical Technology Services, INC. | $911.68 | 2022-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $857.15 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $799.36 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $766.66 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $667.09 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $612.10 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $601.36 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.66 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $502.04 | 2019-2024 | |
| Boston Scientific Corporation | $317.49 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $295.34 | 2019-2023 | Praluent, Evkeeza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274.01 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $255.61 | 2021-2023 | Corevalve Evolut R, Hawkone, Symplicity G3 |
| Alnylam Pharmaceuticals INC. | $192.01 | 2023-2025 | Onpattro, Amvuttra |
| Jenavalve Technology, INC. | $162.44 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $140.18 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $135.40 | 2019-2022 | |
| Scpharmaceuticals INC. | $126.75 | 2024-2025 | |
| Abbott Laboratories | $119.51 | 2021-2023 | Amplatzer Amulet |
| Kiniksa Pharmaceuticals, LTD. | $108.58 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $97.90 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $89.17 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $68.08 | 2022-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $60.16 | 2025 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $59.28 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $54.44 | 2025 | Tryvio |
| Inspire Medical Systems, INC. | $53.89 | 2023-2025 | Inspire |
| Masimo Corporation | $51.22 | 2022-2023 | Set and Rainbow Set |
| Vital Connect, INC | $44.82 | 2025 | Vitalpatch Rtm |
| Chiesi USA, INC. | $44.60 | 2020-2021 | |
| Cook Medical LLC | $39.66 | 2024 | Zilver Ptx |
| Lilly USA, LLC | $38.68 | 2025 | Zepbound, Mounjaro |
| Amryt Pharma Holdings LTD | $32.61 | 2022 | |
| Daiichi Sankyo INC. | $25.41 | 2023 | Injectafer |
| Philips North America LLC | $16.96 | 2020 | |
| Medtronic Vascular, INC. | $15.75 | 2020 | |
| Lundbeck LLC | $15.57 | 2020 | |
| Tactile Systems Technology INC | $15.53 | 2019 | |
| Baxter Healthcare | $14.62 | 2024 | Biopharma Sol - Contract Manuf |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kishin Ramani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.